Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an update.
Telomir Pharmaceuticals announced new laboratory findings demonstrating that Telomir-1 effectively reduces the survival of aggressive pancreatic cancer cells, complementing previous results in other cancer models. The findings suggest potential pathways for treatment, as current therapies are limited by toxicity and resistance, and Telomir plans further preclinical research and in vivo studies.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for aggressive cancer types. The company is known for its work on Telomir-1, a compound targeting cancer cell survival pathways, with a market focus on difficult-to-treat malignancies like pancreatic cancer.
Average Trading Volume: 5,554,657
Technical Sentiment Signal: Sell
Current Market Cap: $53.26M
Find detailed analytics on TELO stock on TipRanks’ Stock Analysis page.